Tonix Pharma (TNXP) has shared an announcement.
Tonix Pharmaceuticals has announced the successful completion of a clinical pharmacokinetic study for Tonmya™, their product candidate, in ethnically Japanese and Chinese volunteers, showing similar key PK parameters to those in Caucasian groups. The study suggests Tonmya is safe and well-tolerated, paving the way for regulatory filings and clinical studies in Japan and China. With patents securing market exclusivity in Asia until 2034, the company plans to initiate Investigational New Drug applications, moving closer to a Phase 3 study in the region, and advancing their competitive position in the market.
For an in-depth examination of TNXP stock, go to TipRanks’ Stock Analysis page.
